Lipopolysaccharides from Porphyromonas gingivalis, Prevotella intermedia and Actinobacillus actinomycetemcomitans promote osteoclastic differentiation in vitro.
Bacterial lipopolysaccharides possess bone-resorbing activity. Here, lipopolysaccharides from three putative periodontopathic bacteria were examined for effects on osteoclast-like cell formation of bone marrow cells from lipopolysaccharide-responsive C3H-HeN and non-responsive C3H/HeJ mice. The bone marrow cells were cultured with or without various doses of lipopolysaccharide in the presence of 1,25-dihydroxyvitamin D3 and dexamethasone. These lipopolysaccharide preparations significantly increased the number of osteoclast-like cells formed in the culture of C3H/HeN marrow cells; the same as lipopolysaccharides from Escherichia coli and a synthetic lipid A with E. coli-type structure (LA-15-PP), at doses from 0.1 to 1 microgram/ml. This stimulating effect of each lipopolysaccharides was uniformly abrogated by the addition of polymyxin B at 5 micrograms/ml. All the lipopolysaccharide and the synthetic lipid A had no effect on osteoclast formation of the C3H/HeJ marrow cells, whereas lipopolysaccharide from Porphyromonas gingivalis and Prevotella intermedia showed significant mitogenic activity on C3H/HeJ spleen cells. It seems likely that the activity of lipopolysaccharides to augment osteoclast-like cell formation in the bone marrow cell cultures is derived from a common structure of the lipid A portion.
Ito
H O
HO
Department of Oral Biochemistry, Kyushu University School of Dentistry, Fukuoka, Japan. hitoded@mbox.nc.kyushu-u.ac.jp
Shuto
T
T
Takada
H
H
Koga
T
T
Aida
Y
Y
Hirata
M
M
Koga
T
T
D000135:Acid Phosphatase / Q000378:metabolism; D016976:Aggregatibacter actinomycetemcomitans / Q000378:metabolism*; D000818:Animals; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D003470:Culture Media; D003907:Dexamethasone / Q000494:pharmacology; D004926:Escherichia coli / Q000378:metabolism; D005938:Glucocorticoids / Q000494:pharmacology; D007527:Isoenzymes / Q000378:metabolism; D008050:Lipid A / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D008815:Mice, Inbred Strains; D008934:Mitogens / Q000494:pharmacology; D010010:Osteoclasts / Q000187:drug effects / Q000473:pathology*; D016966:Porphyromonas gingivalis / Q000378:metabolism*; D018713:Prevotella intermedia / Q000378:metabolism*; D013154:Spleen / Q000187:drug effects / Q000473:pathology; D000071681:Tartrate-Resistant Acid Phosphatase; D014807:Vitamin D / Q000031:analogs & derivatives / Q000494:pharmacology
D003470:Culture Media; D005938:Glucocorticoids; D007527:Isoenzymes; D008050:Lipid A; D008070:Lipopolysaccharides; D008934:Mitogens; D014807:Vitamin D; C097949:1,25-dihydroxyvitamin D; D003907:Dexamethasone; D000135:Acid Phosphatase; D000071681:Tartrate-Resistant Acid Phosphatase